Related Experiment Videos
Production of 105Rh-EDTMP and its bone accumulation
1School of Health Sciences, Faculty of Medicine, Kanazawa University, Japan. ando@kenroku.kanazawa-u.ac.jp
Summary
Rhodium-105 (105Rh) shows promise as a radiotherapeutic agent. A new method efficiently produces pure 105Rh for potential use in treating bone metastases pain.
Area of Science:
- Nuclear medicine
- Radiopharmaceutical chemistry
Background:
- Rhodium-105 (105Rh) possesses advantageous physical properties for radiotherapy.
- Carrier-free 105Rh can be synthesized via neutron activation of 104Ru and subsequent beta decay of 105Ru.
Purpose of the Study:
- To establish a method for producing carrier-free 105Rh suitable for clinical research.
- To evaluate the potential of 105Rh-EDTMP as a therapeutic agent for bone metastases.
Main Methods:
- Neutron activation of 104Ru to produce 105Ru, followed by beta decay to yield 105Rh.
- Synthesis of 105Rh-EDTMP by reacting 105Rh3+ with EDTMP in boiling water.
- Assessment of radiochemical yield and stability using paper chromatography.
- In vivo studies in animals to evaluate blood clearance and bone uptake.
Main Results:
- Carrier-free 105Rh was produced in sufficient quantity and purity.
- 105Rh-EDTMP was synthesized with a radiochemical yield exceeding 99% and demonstrated excellent stability.
- Animal studies revealed rapid blood clearance and selective bone accumulation of 105Rh-EDTMP.
Conclusions:
- The described method effectively produces high-purity, carrier-free 105Rh.
- 105Rh-EDTMP exhibits favorable characteristics for bone-seeking radiopharmaceuticals.
- 105Rh-EDTMP is a promising candidate for managing pain associated with bone metastases.